Results 11 to 20 of about 526 (152)

Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis [PDF]

Nature and Science of Sleep, 2023
Shuqin Zhan,1 Hui Ye,2 Ning Li,1 Yimeng Zhang,1 Yueyang Cheng,1 Yuanqing Wang,1,3 Shimin Hu,1 Yue Hou1 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China; 2Ignis Therapeutics (Shanghai ...
Zhan S, Ye H, Li N, Zhang Y, Cheng Y, Wang Y, Hu S, Hou Y   +7 more
doaj   +2 more sources

Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022. [PDF]

J Sleep Res
Summary Clinicians and people with narcolepsy report varied access to higher‐cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends
van Someren F, Wiedemann M, Warren-Gash C, Sykorova M, Mistry H, Miller MA, Leschziner G, Nolte E, Belot A, Smith IE, Quinnell T, Eriksson SH, Strongman H.   +12 more
europepmc   +4 more sources

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]

EClinicalMedicine
Summary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin, Philippe Lehert, Raoua Ben Messaoud, Marie Joyeux-Faure, Christian Caussé, Jerryll Asin, Ferran Barbé, Maria R. Bonsignore, Winfried Randerath, Johan Verbraecken, Sonya Craig, Yves Dauvilliers   +11 more
doaj   +2 more sources

Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database [PDF]

Frontiers in Pharmacology
ObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou, Jia Chen, Bangtian Xu, Li Chen, Li Chen, Li Chen   +5 more
doaj   +2 more sources

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives

Nature and Science of Sleep, 2021
Vivien C Abad Department of Psychiatry & Behavioral Sciences, Division of Sleep Medicine, Stanford University, Redwood City, CA 94063, USACorrespondence: Vivien C AbadDepartment of Psychiatry & Behavioral Sciences Division of Sleep Medicine ...

exaly   +2 more sources

Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice. [PDF]

Neurotherapeutics, 2023
Wake-promoting agents are used for the management of excessive daytime sleepiness caused by narcolepsy. Clinical and preclinical data suggests that solriamfetol, a novel dopamine and norepinephrine reuptake inhibitor, is a promising therapeutic option for excessive daytime sleepiness.
Sakai N, Nishino S.
europepmc   +3 more sources

Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trialsResearch in context [PDF]

EClinicalMedicine
Summary: Background: Obstructive sleep apnoea (OSA) is a prevalent chronic condition that is associated with cardiometabolic and neurocognitive complications.
Camille Figard, Raoua Ben Messaoud, Sébastien Baillieul, Marie Joyeux-Faure, Marie Destors, Renaud Tamisier, Charles Khouri, Jean-Louis Pépin   +7 more
doaj   +2 more sources

Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management [PDF]

Sleep Medicine: X
Introduction: Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking
Silvia Miano, Leila Kheirandish-Gozal, Marco De Pieri   +2 more
doaj   +2 more sources

Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. [PDF]

Sleep Med, 2023
Obstructive sleep apnea (OSA) is a chronic condition characterized by intermittent hypoxia (IH). Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety. Modafinil (MOD) and Solriamfetol (SOL) are potent wake-promoting agents clinically used to improve wakefulness in OSA patients with EDS ...
Badran M, Puech C, Barrow MB, Runion AR, Gozal D.   +4 more
europepmc   +3 more sources

A Review of Current and Future Pharmacologic Treatments for Narcolepsy [PDF]

European Psychiatry
Introduction Narcolepsy is a rare but disabling neurological disorder involving disruption of the sleep-wake cycle that is often under- or misdiagnosed (Barateau L, et al. J Sleep Res. 2022;31(4):e13631).
P. Chue, J. Chue, M. Tate, A. Andreiev, A. Abba-Aji   +4 more
doaj   +2 more sources